Sulfasalazine lung toxicity is a rare and poorly understood entity, usually taking the form of eosinophilic pneumonia, for which only a handful of case reports can be found in the literature.
Unknown but probably very rare. Occurred twice in a series of 774 patients treated with sulfasalazine monitored for 11 years 2.
Overlap with that of eosinophilic pneumonia. In a 2002 case series comprising of 50 patients 3, the symptoms were distributed as follows:
- classic triad of breathlessness, fever and cough: 42%
- breathlessness: 80%
- fever: 70%
- cough: 64%
- crackles/crepitations/rales: 52%
- less commonly:
- weight loss: 22%
- chest pain: 20%
- rash: 7%
Sulfasalazine is a compound of 5-aminosalicylic acid (5-ASA) and sulfapyridine joined by an azo bond, used in the treatment of chronic inflammatory bowel disease. Fatal toxicity of sulfasalazine is related to blood dyscrasias due to its effects on the bone marrow.
As with eosinophilic pneumonia, a high eosinophil count in bronchoalveolar lavage is characteristic of the condition 3. There is an overlap with other pathological entities, such as organizing pneumonia and acute interstitial pneumonia.
Interestingly, old reports seem to imply that patients with sulfasalazine lung disease also have aspirin allergy 4,5.
- pulmonary infiltrates are the dominant feature
- interstitial infiltrates and ground glass opacities, possibly with upper lobe preference
- can show peripheral nodules, and those can cavitate
- pleural thickening is also reported in a few cases
Treatment and prognosis
It is important to recognize sulfasalazine as the cause of the lung condition as recovery is possible either with sulfasalazine withdrawal or with a corticosteroid course. In a 2002 case series 3, all five deaths due to lung toxicity were patients with ulcerative colitis and it is possible there are unknown factors contributing to these deaths.
- 1. Nadarajan P, Fabre A, Kelly E. Sulfasalazine: A rare cause of acute eosinophilic pneumonia. (2016) Respiratory medicine case reports. 18: 35-6. doi:10.1016/j.rmcr.2016.03.006 - Pubmed
- 2. Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. (1986) British medical journal (Clinical research ed.). 293 (6544): 420-3. doi:10.1136/bmj.293.6544.420 - Pubmed
- 3. S.D. Parry, C. Barbatzas, E.T. Peel, J.R. Barton. Sulphasalazine and lung toxicity. (2002) European Respiratory Journal. 19 (4): 756. doi:10.1183/09031936.02.00267402 - Pubmed
- 4. Wang KK, Bowyer BA, Fleming CR, Schroeder KW. Pulmonary infiltrates and eosinophilia associated with sulfasalazine. (1984) Mayo Clinic proceedings. 59 (5): 343-6. doi:10.1016/s0025-6196(12)61431-1 - Pubmed
- 5. Jones GR, Malone DN. Sulphasalazine induced lung disease. (1972) Thorax. 27 (6): 713-7. doi:10.1136/thx.27.6.713 - Pubmed